干扰素联合利巴韦林治疗老年慢性丙型肝炎的疗效及安全性4例报告

蔡少平; 张文瑾; 何卫平; 范振平; 吉英杰

doi:10.3969/j.issn.1001-5256.2014.01.019

干扰素联合利巴韦林治疗老年慢性丙型肝炎的疗效及安全性4例报告

DOI: 10.3969/j.issn.1001-5256.2014.01.019

解放军第302医院军人肝病科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2983
- HTML全文浏览量: 8
- PDF下载量: 621
- 被引次数: 0
出版历程
- 出版日期: 2014-01-20

Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases

Liver Disease Center for Military Staff, 302 Hospital of PLA

摘要

摘要: <正>干扰素联合利巴韦林为目前治疗丙型肝炎的标准治疗方法[1]。但老年患者合并高血压病、心脏病、糖尿病等基础性疾病较多,耐受性差,限制了干扰素的应用,尤其大于70岁的高龄老人中应用干扰素的病例较少。为观察干扰素联合利巴韦林治疗的疗效及安全性,作者对抗病毒愿望强烈的患者,在充分评估并在患者及家属充分知情同意并共同签署同意书后,对4例年龄超过70岁的老年慢性丙型肝炎患者给予干扰素联合利巴韦林治疗,现报道如下。
- 肝炎,丙型,慢性 /
- 老年人 /
- 干扰素 /
- 利巴韦林
- hepatitis C, chronic /
- aged /
- interferon /
- ribavirin

HTML全文

参考文献(10)

[1]LI MR, SUN XL, REN GF, et al.Clinical oloservation of pegylated interferon alpha-2a combined voith ribavirin in the treatment of chronic hepatitis C[J].Int J Virol, 2013, 20 (1) :22-23. (in Chinese) 李敏然, 孙杏丽, 任桂芳, 等.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的临床观察[J].国际病毒学杂志, 2013, 20 (1) :22-23.

[2]CAO JJ, XUE BY.Study on traditional Chinese medicine treatment of hepatic C[J].J Changchun Univ Tradit Chin Med, 2012, 28 (2) :71-73. (in Chinese) 曹静静, 薛博瑜.中医药治疗丙型肝炎的研究[J].长春中医药大学学报, 2012, 28 (2) :71-73.

[3]WANG XF, CHENG YQ, ZHANG WJ, et al.Course analysis:from HCV infection to hepatocellular carcinoma[J].Chin Hepatol, 2004, 9 (1) :8-10. (in Chinese) 王晓峰, 程勇前, 张文瑾, 等.丙型肝炎病毒感染至临床诊断肝癌的病程经过[J].肝脏, 2004, 9 (1) :8-10.

[4]MIKI D, AIKATA H, UKA K, et al.Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma[J].J Gastroenterol, 2008, 43 (7) :550-557.

[5]HONDA T, KATANO Y, SHIMIZU J, et al.Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis[J].Liver Int, 2010, 30 (4) :527-537.

[6]LIU XM, DUAN ZH, WANG KF, et al.Analysis of effect factors of antiviral therapy outcome for 60 cases of elder hepaitits C patients[J/CD].Chin J Clin:Elentronic Edition, 2012, 6 (10) :2648-2651. (in Chinese) 刘雪梅, 段忠辉, 王克菲, 等.老年丙型肝炎患者60例抗病毒疗效影响因素分析[J/CD].中华临床医师杂志:电子版, 2012, 6 (10) :2648-2651.

[7]ZHENG YY, FAN XH, WANG LF, et al.Efficacy and side effect of PEG-IFNα-2a plus ribavirin on elderly patients with chronic hepatitis C[J].J Clin Hepatol, 2011, 27 (8) :821-823. (in Chinese) 郑颖颖, 范晓红, 王力芬, 等.聚乙二醇干扰素α-2a联合利巴韦林治疗老年慢性丙型肝炎的疗效和安全性[J].临床肝胆病杂志, 2011, 27 (8) :821-823.

[8]YAN Q, NA LL, WANG Y.Low-dose interferon incremental solutions in the treatment of 10 cases of elder patients with chronic hepatitis C[J].Harbin Med J, 2009, 29 (1) :15. (in Chinese) 严勤, 那琳琳, 王莹.小剂量干扰素递增方案治疗10例老年慢性丙型肝炎[J].哈尔滨医药, 2009, 29 (1) :15.

[9]CHENG YQ, QING S, DING N, et al.Introduction of typical cases of HCV infection in elder patients and adjustment of antiviral treatment strategies[J].J Clin Hepatol, 2012, 15 (5) :459-460. (in Chinese) 程勇前, 卿松, 丁宁, 等.老年HCV感染典型病例介绍及抗病毒治疗策略调整[J].实用肝脏病杂志, 2012, 15 (5) :459-460.

[10]JIANG XQ, ZOU XJ, TIAN DY.Virological response of chronic hepatitis C treated with peg-interferonα-2a and ribavirin[J].J Clin Hepatol, 2011, 27 (4) :417-419. (in Chinese) 姜雪强, 邹小静, 田德英.聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者的病毒学应答[J].临床肝胆病杂志, 2011, 27 (4) :417-419.

施引文献

资源附件(0)

访问统计